| Ytd | 97.34% | |
| 1y | 57.20% |
| Open | 11.14 | Prev Close | 11.13 | Low | 11.10 | High | 11.25 | Mkt Cap | 994.04M |
| Vol | 0.00 | Avg Vol | 5.72M | EPS | -2.11 | P/E | -5.27 | Forward P/E | -2.04 |
| Beta | 2.23 | Short Ratio | 11.25 | Inst. Own | 97.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 8.21 | 200-d Avg | 6.45 | 1yr Est | 26.20 |
VERV News
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reaso
INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the s
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutic
Investing in biotechnology stocks is similar to the drug development process itself. That is, invest
Shares in Verve Therapeutics (VERV -0.54%) soared 80.5% this week on the news of an agreement for El
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEA
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
Shares of Verve Therapeutics (VERV 76.24%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tue
Biotech stock Verve Therapeutics Inc (NASDAQ:VERV) is up 75.3% to trade at $10.99 at last check amid
Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing compa
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breach
Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a poten
Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.
Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by
A report said the two pharmaceutical companies are in advance talks.
Eli Lilly and Co (NYSE:LLY) is in advanced discussions to acquire Verve Therapeutics in a deal worth
Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 bil
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
During Thursday, 849 stocks hit new 52-week lows.